Secondary endpoints will include quality of life measurements.

Aeruginosa Colony Forming Units reduced by a mean 1.43 log over the 14-day treatment period . Evaluation seven days after research treatment was discontinued demonstrated that the P. Aeruginosa bacterial density was still reduced by 1.02 log CFU from the baseline without extra antibiotic use. Pulmonary function screening as measured by the pressured expiratory volume in a single second showed a substantial mean increase of 6.9 percent from baseline after 2 weeks of treatmentData from this new IND study will support inclusion of young CF patients in our future pivotal trials, said Dr.Bayer: Research For A Better Lifestyle Bayer is a worldwide enterprise with primary competencies in the areas of healthcare, agriculture and high-tech polymer components. As an innovation organization, it sets tendencies in research-intensive areas. Bayer’s services and products are designed to advantage people and enhance their quality of lifestyle. Simultaneously, the Group aims to create value through technology, growth and high generating power. Bayer is focused on the concepts of sustainable development also to its public and ethical obligations as a corporate citizen. In fiscal 2013, Bayer employed some 113,200 people and had product sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenditures to EUR 3.2 billion.

Bluecross awards UTHSC $2,912,751 grant to market patient safety The University of Tennessee Wellness Science Middle has been awarded a $2,912,751 grant from the BlueCross BlueShield of Tennessee Wellness Foundation to invest in its Promoting Patient Basic safety Through Teamwork-Focused Interdisciplinary Simulations Plan.